Document is current
Any future updates will be listed below
-
Authors
Ganz, Tomas https://orcid.org/0000-0002-2830-5469
- License Information
-
More Information
Article History
First Online: 10 March 2022
Competing interests
: T.G. is a shareholder in Intrinsic LifeSciences and Silarus Pharma and has received consulting fees from Alnylam Pharmaceuticals, Akebia Therapeutics, Disc Medicine, FibroGen/AstraZeneca, Global Blood Therapeutics, Gossamer Bio, Ionis Pharmaceuticals, Pharmacosmos, Rallybio, Sierra Oncology and Silence Therapeutics.
